The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies

The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies

For patients with hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) or arrhythmogenic cardiomyopathy (ACM), screening for pathogenic variants has become standard clinical practice. Genetic cascade screening also allows the identification of relatives that carry the same mutation as the...

Full description

Bibliographic Details
Main Authors: Nienke M. Stege, Rudolf A. de Boer, Maarten P. van den Berg, Herman H. W. Silljé
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:International Journal of Molecular Sciences
Subjects:
plasma biomarkers
genetic cardiomyopathy
early detection
noncoding RNA
cardiac autoantibodies
HCM
Online Access:https://www.mdpi.com/1422-0067/22/6/2955

Internet

https://www.mdpi.com/1422-0067/22/6/2955

Similar Items